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Abstract
Prion diseases are fatal, neurodegenerative disorders in humans and animals and are characterized by the accumulation of
an abnormally folded isoform of the cellular prion protein (PrP
C), denoted PrP
Sc, which represents the major component of
infectious scrapie prions. Characterization of the mechanism of conversion of PrP
C into PrP
Sc and identification of the
intracellular site where it occurs are among the most important questions in prion biology. Despite numerous efforts, both
of these questions remain unsolved. We have quantitatively analyzed the distribution of PrP
C and PrP
Sc and measured PrP
Sc
levels in different infected neuronal cell lines in which protein trafficking has been selectively impaired. Our data exclude
roles for both early and late endosomes and identify the endosomal recycling compartment as the likely site of prion
conversion. These findings represent a fundamental step towards understanding the cellular mechanism of prion
conversion and will allow the development of new therapeutic approaches for prion diseases.
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Introduction
Conversion of the cellular prion protein (PrP
C) into a
conformationally altered pathogenic form, denoted PrP scrapie
(PrP
Sc) is the central event in the pathogenesis of transmissible
prion diseases [1]. In the most accredited model of prion
formation and replication, a direct interaction between the
pathogenic PrP
Sc template and the endogenous PrP
C substrate is
proposed to drive the formation of nascent infectious prions [1].
Despite decades of research, the mechanism of prion conversion,
the intracellular site where this process occurs and how it leads to
neurological dysfunction remain unknown [2].
A number of studies have already attempted to identify
subcellular location(s) where prion conversion occurs, mostly by
analyzing PrP
C and PrP
Sc subcellular distribution and trafficking
in infected cell lines [3,4], primary neurons [5,6,7] and in the
brains of infected animals [8,9,10,11,12] using different tech-
niques. However, these results remain controversial and do not
provide clear evidence for the involvement of any specific
compartment.
PrP
C has been shown to localize to different compartments
depending on the cell type. While Pimpinelli et al. reported a
predominant localization in late endosomes of neuroblastoma-
derived (N2a) and hypothalamic gonadotropin releasing (GT1-7)
cell lines [13], other studies have reported that in primary neurons
and in N2a cells PrP
C is internalized and recycled back to the cell
surface, with very little being localized in lysosomes [6,7].
Furthermore, a chimeric protein fused with GFP (GFP-PrP
C)
expressed inSN56 cellsderived from septalcholinergic neurons, has
been detected in the Golgi, early endosomes (EEs), and in the
endosomal recycling compartment (ERC) [14]. In hippocampal
neurons, PrP
C is found principally at the plasma membrane [5] and
on vesicles resembling early endocytic or recycling vesicles [12].
Less information is available about the intracellular localization
of PrP
Sc. This is mainly due to the lack of specific antibodies and
the need for protein denaturation by guanidine-hydrochloride
(Gnd) in order to reveal PrP
Sc epitopes [15]. Earlier work reported
that the majority of PrP
Sc is intracellular [15], sequestered within
lysosomes of scrapie-infected N2a cells [3,16,17] with little
localization at the cell surface [18]. In infected brains, PrP
Sc has
been reported to accumulate at the plasma membrane and
occasionally in late endosome/lysosome-like structures [10]. More
recent reports describe accumulation of PrP
Sc either in the
perinuclear Golgi region of neurons in scrapie-infected transgenic
mice [11], in the late endosomal compartment in infected GT1-7
and N2a cells [13] and at the cell surface and on early endocytic
and recycling vesicles of hippocampal neurons [12]. Furthermore
exogenous Alexa-labeled PrP
Sc was shown to be internalized into
vesicles positive for late endosomal/lysosomal markers in SN56
cells and hamster cortical neurons [14].
Several studies indicate that PrP
Sc is formed after PrP
C has
reached the plasma membrane [3,19,20,21]. Furthermore, the
endocytic pathway has been proposed to be important for the
conversion of PrP
C to PrP
Sc, based on the observation that release
of nascent PrP from the cell surface using phosphatidylinositol-
specific phospholypase C, or inhibition of endocytosis using a
temperature block prevented PrP
Sc synthesis [2,3]. Moreover,
PrP
Sc is cleaved at its N-terminus by endogenous proteases in
acidic compartments immediately after its generation [3,16],
suggesting that its conversion to a protease-resistant state occurs
prior to its exposure to proteases within an endo-lysosomal
compartment. Furthermore, the expression of a dominant-
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the plasma membrane, increases the production of PrP
Sc in
infected N2a cells supporting the hypothesis that PrP
Sc formation
does not require cell-surface recycling and occurs in an
intracellular compartment [4]. Although no specific compartment
has been identified, altogether these data provide good evidence
that PrP
Sc may be generated either at the cell surface or more
likely along the endocytic pathway.
Proteins have been shown to enter the cell through many
different routes (for review see [22]; however, regardless of the
internalization pathway used, cargo is first delivered to early
endosomes. At this level cargo to be recycled is returned to the cell
surface either by a fast-recycling pathway, directly from early
endosomes, or it is transported first to the endosomal recycling
compartment and then to the cell surface. In contrast, cargo
destined for degradation is sorted to multivesicular late endosomes
and finally to lysosomes, where degradation occurs (for review see
[23,24] and see below). Importantly, Rab GTPases, which reside in
different subcellular compartments, have been identified as central
regulators of intracellular transport, controlling specific fusion
between vesicles and different compartments (for review see [25]).
The aim of the current study was to identify the subcellular
compartment(s) of PrP
Sc production. To this end we set up a
quantitative image analysis system and monitored PrP
C and PrP
Sc
localization and PK-resistant PrP levels under different experimen-
tal conditions in three different neuronal cell lines (N2a, GT1 and
CAD cells) that represent established cell models for prion infection
and replication [26,27]. We show here that at the steady-state high
amounts of PrP
Sc reside in the endosomal recycling compartment
(ERC). Then by selectively perturbing PrP trafficking through the
endosomal compartments we excluded roles for both early and late
endosomes in prion conversion and provide evidence that this event
occurs in the endosomal recycling compartment.
Results
Steady-state localization of PrP
C and PrP
Sc in ScGT1 cells
Because the subcellular distribution of PrP forms may yield clues
as to the site of prion conversion, we quantitatively analyzed the
intracellular distribution of PrP
C and PrP
Sc in infected GT1 cells
(ScGT1) by using specific antibodies and a high resolution wide-
field microscope (Marianas, Intelligent Imaging Innovations)
together with different imaging software packages (see Methods).
Based on colocalization with different organelle markers, we found
,20% of PrP
C localized in the Golgi (Figure 1A, upper panels and
Figure 1E), ,15% in early endosomes (EEs) (Figure 1C, upper
panels and Figure 1E), ,15% in the endosomal recycling
compartment (ERC) (Figure 1D, upper panels and Figure 1E)
and only ,3% in late endosomes (LEs) (Figure 1B, upper panels
and Figure 1E). The majority of the protein (,50%) was localized
at the cell surface (data not shown). Interestingly, we observed the
same distribution of PrP
C in uninfected GT1 cells, indicating that
PrP
Sc infection did not alter PrP
C trafficking in GT1 cells (data not
shown). Interestingly, in two other infected neuronal cell lines,
ScCAD and ScN2a, PrP
C was almost exclusively localized at the
cell surface (data not shown).
Due to the lack of PrP
Sc - specific antibodies [15] in order to
visualize PrP
Sc, a denaturation step with guanidine hydrochloride
(Gnd) is required. However, this treatment does not allow one to
easily distinguish PrP
Sc from PrP
C. In contrast to previous studies,
we took advantage of the features of our imaging system to
discriminate PrP
Sc from PrP
C by adjusting the signal threshold,
and recording only the higher signal intensities characteristic of
PrP
Sc staining after Gnd treatment in infected cells (see Methods,
Figure S1 and [28]). Because we were concerned that with this
stringent approach we would detect mainly the brighter PrP
Sc
signal which could derive from large aggregates, we performed
velocity gradients in order to analyze the state of PrP aggregation,
similar to what has been shown before in brain [29]. Interestingly,
we did not observe any difference in the distribution of PrP on the
gradients between uninfected cells containing only PrP
C and
infected cells containing both PrP
C and PrP
Sc, thus arguing against
the presence of large PrP
Sc aggregates in our cell model (data not
shown) in contrast to what was described before in infected brains
[29,30]. These data, although indirectly, support the use of this
thresholding procedure to reveal (with a reasonable approxima-
tion) the intracellular distribution of all PrP
Sc in infected cells as
recently shown [28,31]. By this approach we observed that unlike
PrP
C, only ,10% of PrP
Sc was localized at the cell surface (data
not shown), while ,90% was found to be intracellular as
previously described [15,18]. However, in contrast to earlier
reports [11,13,17] we did not observe any localization of PrP
Sc in
the Golgi compartment (Figure 1A lower panel) the majority of the
intracellular protein being localized throughout the endocytic
pathway. While only ,10% of the protein was localized in LEs
(Figure 1B lower panels and Figure 1E) and EEs, (Figure 1C lower
panels and Figure 1E) more than 25% was found in the ERC
(Figure 1D lower panels and Figure 1E). Interestingly, a similar
distribution of PrP
Sc was observed in ScCAD and ScN2a cells
(Figure S2). Therefore, the greater amount of PrP
Sc in the ERC
when compared to other subcellular sites could indicate a potential
involvement of this compartment in the conversion process.
Alternatively, the ERC could just represent the compartment
through which PrP
Sc recycles after being converted elsewhere (eg.
at the cell surface, in EEs or in LEs, which have previously been
proposed as sites of conversion) [17,32,33]. To directly examine
this question we selectively perturbed the trafficking through the
different endosomal compartments using pharmacological inhib-
itors or mutant proteins affecting the different pathways.
Impaired exit from early endosomes reduces PrP
Sc levels
To examine the role of the late endocytic pathway in prion
conversion, we treated ScGT1 cells with U18666A. This
Author Summary
The misfolded form (PrP
Sc or prion) of the naturally occuring
prion protein (PrP
C or cellular PrP) is responsible for
neurodegenerative diseases such as Creutzfeldt-Jakob dis-
ease (CJD), bovine spongiform encephalopathy (BSE) (also
known as ‘mad cow disease’) and a new variant of CJD
(vCJD), which is thought to be caused by ingestion of cattle-
derived foodstuffs contaminated with prions. These diseases
are characterized by the accumulation of protein deposits in
the central nervous system (CNS). However, unlike other
neurodegenerative diseases, prion diseases are infectious
and prions are able to propagate in a chain reaction by
imposing their malconformed state onto the properly folded
cellular proteins. Understanding where the conversion of
PrP
C into PrP
Sc occurs in cells has been an unsolved question
until now. By analysing the intracellular localization of PrP
C
and PrP
Sc and measuring the levels of PrP
Sc produced in
infected neuronal cell lines under conditions in which
intracellular trafficking of the protein is impaired, we found
that prion conversion occurs in the endosomal recycling
compartment (ERC) where it transits after being internalized
from the cell surface. This studywill help to clarify the cellular
mechanism of the disease and it opens the way to new
therapeuticstrategiesaimedattheconversioncompartment.
Prion Conversion Compartment
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by an as of yet unknown mechanism [34]. As a consequence, it
effectively inhibits trafficking from EEs to LEs, because Annexin
II, which is coordinating this step is redistributed into cholesterol
laden LEs. In addition, exit from LEs to the Golgi and lysosomes is
inhibited and protein degradation is impaired [35,36]. After
treating ScGT1 cells with U18666A for 6 days, we observed a
complete disappearance of Proteinase K (PK) resistant PrP
Sc,a s
shown by limited proteolysis using the PK assay (Figure 2A and see
the explanation in Methods). We also observed an increase in total
PrP
C levels as expected because of the known effect of U18666A
on protein degradation [35] (Figure 2A). Therefore, under these
conditions the reduction in PrP
Sc was likely due to inhibition of
PrP
Sc production rather than its increased degradation. Interest-
ingly, PrP
Sc reduction following U18666A treatment was previ-
ously reported in ScN2a cells and was attributed to the
redistribution of PrP
C outside of cholesterol and glycosphingolipids
enriched membrane microdomains, known as detergent-resistant
domains (DRMs) or lipid rafts [37]. This is conceivable
considering the effect of this drug on cholesterol and sphingolipid
trafficking [38]. However, although we could reproduce the results
in ScN2a cells (Figure S3A), we did not observe any effect of
U18666A on the association of PrP
C with DRMs neither in ScN2a
(Figure S3B) nor in ScGT1 cells (Figure 2B), thus refuting the
above hypothesis. In contrast, we observed that in both cell lines
U18666A treatment altered the subcellular distribution of PrP
C,
which became highly enriched (,40%) in EEs after the treatment
(compare control cells with treated cells in Figure 2C and Figure
S3C, and see quantification of EEA-1/PrP colocalization in
Figure 2D). Therefore, these data suggest that U18666A affects
PrP conversion by altering its intracellular trafficking. Further-
more, they also indicate that PrP
C must exit the EE compartment
in order to be converted to PrP
Sc.
To identify the pathway involved in prion conversion we had to
determine to what extent the U18666A treatment affected
endocytic pathways in ScGT1 cells. To this aim we analysed the
trafficking of two molecules widely used to characterize trafficking
through endocytic compartments: dextran, which traffics through
EEs and reaches LEs, and transferrin (Tfn) which recycles back to
the surface through EEs and the ERC. By following fluid phase
uptake of fluorescently tagged dextran (Figure S4) we confirmed
that U18666A also inhibits the traffic from EEs to LEs in ScGT1
cells (Figure S4B) as previously reported for other cell types
[35,36]. Furthermore, by staining cholesterol with filipin, we also
show that U18666A causes enlargement of LEs, which accumulate
cholesterol (see large organelles in Figure S4B, costained with
filipin and LBPA). In addition to this well documented effect, we
found that in U18666A treated cells fluorescently tagged Tfn was
Figure 1. Steady state distribution of PrP
C and PrP
Sc in ScGT1 cells. PrP was immunolabeled with SAF32 mAb and colocalization with (A)
Giantin (Golgi), (B) LBPA (late endosomes), (C) EEA-1 (early endosomes) and (D) Alexa 488-transferrin (Tfn, marker for the endosomal recycling
compartment) was analyzed. Exp 500 ms and exp 100 ms represent the exposure times used to detect immunofluorescent signal coming from PrP
C
and PrP
Sc respectively. Yellow color and arrowheads indicate colocalization. Nuclei are stained with DAPI (blue). Insets represent magnifications of the
boxed areas. Scale bars represent 10 mm. (E) Quantification of PrP
C and PrP
Sc colocalization with LBPA, Giantin, EEA-1 and Alexa 488-transferrin.
doi:10.1371/journal.ppat.1000426.g001
Prion Conversion Compartment
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was still arrested in EEs both in ScGT1 (Figure 3B) and ScN2a
cells (Figure S3D). Nonetheless, we observed that, similar to
control ScGT1 cells, Tfn could not be detected inside the cells
after a 45 minutes chase period (compare panels c and d in
Figure 3), indicating that under these conditions Tfn recycling to
the surface via EEs was unaffected. These data therefore show that
prolonged treatment with U18666A did not alter arrival to EEs
nor recycling from EEs to the PM but inhibited trafficking
pathways both between EEs and LEs and between EEs and the
ERC. Since endogenous PrP
C accumulates in EEs in the presence
of U18666A (Figures 2C and 2D), overall these results indicate
that EEs (and recycling from EEs to the PM) are not involved in
PrP
Sc production, while exit of PrP from EEs towards either the
ERC or LEs is required for conversion to occur. Therefore we
decided to selectively inhibit these two pathways and to analyze
the effect on scrapie production.
Late endosomes are not involved in prion conversion
In order to directly test whether LEs/lysosomes are involved in
PrP
Sc production, we used an RNAi approach to downregulate
Alix, a protein that is required for the biogenesis of LEs [39]
(Figure S5A). We obtained a clear reduction of protein levels
(,80%) after transfection of Alix siRNA in ScGT1 and ScCAD
cells (Figure 4A and Figure S5B), but not in ScN2a cells (data not
shown). Consistent with previous findings in HeLa cells [39] the
number of LEs and lysosomes in transfected ScGT1 cells was
drastically reduced (,10 fold) (compare top and bottom panels in
Figure S5A and quantifications). However, despite the drastic
reduction in the number of LEs, the levels of total PrP and PrP
Sc
were unaltered in Alix-depleted ScGT1 cells. Instead, we observed
a slight increase in PrP
Sc as well as total PrP, likely due to the
reduction in protein degradation in cells with fewer LEs/lysosomes
(Figure 4A). Interestingly, we could also reproduce these data in
ScCAD cells (Figure S5B), indicating that the effect of Alix
depletion on PrP
Sc was not limited to a single infected cell line.
Overall, these data demonstrate that PrP transport to LEs is not
required for PrP
Sc production and rule out the involvement of LEs
in scrapie conversion. Interestingly, we observed that Alix
depletion did not affect the intracellular localization of PrP
C and
PrP
Sc, which were found to be enriched in the ERC similar to
control cells (Figure 4B, compare colocalization with Tfn in
Figure 2. U18666A reduces PrP
Sc levels and impairs PrP
C trafficking in ScGT1 cells, without affecting PrP distribution in DRMs. (A)
Levels of total PrP (PK2) or PrP
Sc (PK+) were analyzed on western blot in control cells (ctrl) and cells treated with U18666A. Increased PrP
C and
decreased PrP
Sc levels were observed in treated cells. (B) Lysates from control and U18666A treated ScGT1 cells were applied on sucrose gradients
and ultracentrifuged at 200000 g for 16 hr. Twelve fractions were collected and proteins were precipitated using 10% of trichloroacetic acid. PrP and
flotillin-1 contents in each fraction were analyzed on western blot using SAF61 mAb and flotillin-1 mAb. Fractions 4–7 correspond to detergent
resistant membranes (DRM) based on distribution of flotillin-1, which is mainly present in DRMs. In ScGT1 cells PrP is distributed in DRMs and
U18666A treatment does not change its distribution. (C) Steady-state localization of PrP
C was analyzed in control (ctrl) and U18666A-treated ScGT1
cells. Yellow color and arrowheads represent colocalization between PrP
C and EEA-1. Scale bars represent 10 mm (D) Quantification results are
presented as % (mean6s.e.m, n=80) of total PrP
C signal (red) colocalizing with EEA-1 signal (green) (p=0,014, t-test).
doi:10.1371/journal.ppat.1000426.g002
Prion Conversion Compartment
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C (2Gnd) and PrP
Sc (+Gnd) and
see quantification in the right panel), thus, pointing to a role for
this compartment in prion conversion.
Impaired recycling from early endosomes does not affect
PrP
Sc levels
In U18666A-treated cells Tfn delivery to the ERC was inhibited
(Figure 3B) but its recycling to the surface from EEs was unaffected
(Figures 3C and 3D). Under the same conditions, PrP was
enriched in EEs (Figure 2B). These data suggest that ERC-
independent recycling to the surface via EEs is not likely to be
relevant for PrP
Sc production. Consistent with this hypothesis
expression of a dominant-negative Rab4 mutant (GFP-
Rab4N121I), which impairs recycling from EEs [40], did not
affect PrP
Sc levels in either ScGT1 or ScN2a cells (Figure S6).
Interestingly, it was previously reported that in ScN2a cells the
same Rab4 dominant-negative mutant increased scrapie levels [4].
Although in our hands the levels of PrP
Sc remained unaltered in
ScN2a cells transfected with Rab4 dominant-negative, both of
these sets of data concur in showing that recycling from EEs to the
PM is not involved in scrapie production.
PrP sorting to the endosomal recycling compartment is
required for PrP
Sc production
To directly test whether PrP
C must reach the ERC in order to
be converted to PrP
Sc we analyzed the effect of Rab22a
overexpression on PrP sorting and PrP
Sc production. Rab22a
has been shown to regulate Tfn sorting from EEs to the ERC [41]
and to be involved in sorting of MHCI from the ERC into tubular
carriers destined for the cell surface [42]. In CHO cells
overexpression of GFP-Rab22a causes a characteristic enlarge-
ment of EEs [41], probably due to enhanced homotypic fusion of
Rab22-containing vesicles. This prevents segregation of the
domains required for fusion with other compartments, resulting
in delayed transport out of EEs. As a consequence, Tfn
accumulates in this compartment [41]. Importantly, Rab22
overexpression in CHO cells does not impair protein delivery
from EEs to LEs. In contrast to CHO cells, when GFP-Rab22a is
overexpressed in HeLa cells it localized to the ERC and to tubular
carriers and does not affect either the distribution or the recycling
of Tfn [42]. In order to see whether in our infected cell models
Rab22a was acting as a specific effector of trafficking between EEs
and the ERC, we analyzed the subcellular distribution of GFP-
Rab22a and the effect of its overexpression on Tfn trafficking in
our three infected cell models. Similar to CHO cells, in transfected
ScGT1 cells we observed enlarged EEA-1 positive EEs decorated
with GFP-Rab22a (Figure 5A). We also found that the transfected
cells were able to internalize Tfn normally (Figure S7A). However,
in contrast to control cells, Tfn was not transported to the ERC
after internalization, but remained inside EEs (,80%) (Figure
S7A). Similarly PrP was enriched in the EEs of Rab22a-transfected
ScGT1 cells (Figure 5A) as shown by quantification of its co-
localization with EEA-1 (see graph in Figure 5A). These data
therefore indicate that, like Tfn, PrP was not able to reach the
ERC in Rab22a-transfected ScGT1 cells. Interestingly, by
performing PK assay we observed that while total PrP levels were
unchanged, there was ,50% decrease in PrP
Sc levels in GFP-
Figure 3. U18666A blocks transferrin trafficking from EE to ERC but does not interfere with Tfn delivery to the cell surface. (A)
Recycling of Alexa 488-transferrin (Tfn) was analyzed in control ScGT1 cells. A diffused cholesterol distribution was revealed by filipin staining (blue).
Yellow color and arrowheads indicate colocalization between Tfn and EEA-1. Inset represents magnification of the boxed area. (B) The same
experiment described in (A) was performed in ScGT1 cells treated with U18666A for 6 days. Characteristic large cholesterol laden endosomes were
revealed by fillipin staining (blue). Note that in contrast to control cells, in treated cells Tfn was not transported to ERC 15 min post-internalization.
Alexa 488-transferrin was chased out of both control (C) and U18666A (D) treated cells after 45 min. Scale bars represent 10 mm.
doi:10.1371/journal.ppat.1000426.g003
Prion Conversion Compartment
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GFP alone (Figure 5B, middle and right panels). This partial
decrease in PrP
Sc levels corresponded to the transfection efficiency,
which was approximately 50% (data not shown). In agreement
with the biochemical data, when GFP-Rab22a transfected cells
were analyzed by immunofluorescence after Gnd treatment, no
PrP
Sc signal could be observed in GFP-Rab22a-expressing cells
(Figure 5C). Interestingly, like in ScGT1 cells, GFP-Rab22a was
mainly localized in enlarged EEA-1 positive endosomes in
transfected ScCAD cells (Figure S8A, upper panels). However, a
substantial amount of GFP-Rab22a was also found in perinuclear
tubular structures (Figure S8A upper panels, arrowheads) and
vesicles lacking EEA-1 (Figure S8A upper panels, arrows). Despite
this heterogenous distribution, sorting of Tfn from EEs to the ERC
was impaired in GFP-Rab22a expressing CAD cells similar to
ScGT1 cells (Figure S8A lower panels). Therefore, as expected,
Rab22a expression also caused redistribution of PrP
C to EE and
decreased PrP
Sc production in this cell line similar to what was
observed in ScGT1 cells (Figures S8B, S8C and S8D). In contrast,
in ScN2a cells, Rab22a behaved similarly to HeLa cells and did
not inhibit the trafficking of Tfn from EEs to the ERC.
Consequently, overexpression of Rab22a in ScN2a cells did not
have any effect on the levels of PrP
Sc (data not shown). Although
these data indicate that PrP
C must reach the ERC in order to be
converted, we had to rule out the possiblity that overexpressed
Rab22a was titrating out other cellular sorting factors. To this end,
we used a complementary approach and downregulated endog-
enous Rab22a using siRNA. Given the role of Rab22 in cargo
sorting towards the ERC [41], depletion of Rab22a should cause a
delay in transport from EEs, resulting in the same effect as Rab22
overexpression. As expected, when endogenous Rab22a was
depleted from ScGT1 cells a similar decrease in PrP
Sc levels was
obtained (Figure S7B).
Altogether, these data indicate that a block of PrP
C trafficking
from EEs to the ERC reduces levels of PrP
Sc in infected cells of
different neuronal origin. Nonetheless, they do not allow us to
discriminatewhetherthereductioninPrP
Sclevelsisduetoimpaired
production or to enhanced degradation of PrP
Sc. In particular, it is
possible that impairment of PrP recycling in GFP-Rab22a
expressing cells could divert PrP towards a degradation pathway.
To rule out this hypothesis we monitored the distribution of PrP
Sc
and Alexa-546 dextran in ScGT1 cells expressing GFP-Rab22a
three days post-transfection, when the reduction of PrP
Sc was not
complete and when we could still detect PrP
Sc in the transfected
cells. Under these conditions dextran was mainly found in LEs after
the 3 h chase period (Figure 6A, lower panels), confirming that
Rab22a did not affect the routing of dextran from EEs to LEs [41].
Conversely, only a minority of PrP
Sc was localized in LE under
these conditions similar to control cells (Figure 6A, upper panels,
arrows). Therefore, these data indicate that in GFP-Rab22a-
expressing cells PrP was not diverted toward LEs. Instead, a
significant amount of PrP
Sc wasdistributed in GFP-Rab22a-positive
EEs, similar to what was observed for PrP
C (Figure 6A, upper
panels, arrowheads and Figure 5A). Altogether, these results
indirectly suggest that the observed decrease in PrP
Sc levels in
Rab22-expressing cells is not due to increased delivery and
Figure 4. Alix downregulation in ScGT1 cells does not affect PrP localization and PrP
Sc levels. (A) Alix, PrP
Sc (PK+) and total PrP (PK2)
levels were analyzed on western blot in control (ctrl) cells and cells transfected either with control oligo (ctrl ol) or RNAi against Alix (siAlix). The band
corresponding to Alix is marked by an arrow. Asterisk indicates unspecific band as a control for equal loading. Slightly increased levels for total PrP
(p=0,038) and PrP
Sc (p=0,018) were observed upon Alix downregulation. (B) Steady state distribution of PrP
C (2Gnd) and PrP
Sc (+Gnd) in control
(ctrl) and Alix depleted cells (siAlix) was analyzed by immunofluorescence. Alix depleted cells containing significantly less LBPA positive vesicles (blue)
are marked by asterisk. Yellow color and arrowheads indicate colocalization between PrP and Tfn. The quantification results (mean6s.e.m, n=80) are
presented as % of total PrP signal (red) colocalizing with Tfn (green). Note that no difference was observed in PrP
C (p=0,83, t-test) and PrP
Sc (p=0,52,
t-test) colocalization with transferrin in control condition and upon Alix downregulation. Scale bars represent 10 mm.
doi:10.1371/journal.ppat.1000426.g004
Prion Conversion Compartment
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Sc in LEs, but rather is due to impaired scrapie
production. To further test this hypothesis and to discriminate
between increased degradation and decreased production of PrP
Sc,
we compared the levels of PrP
Sc in control cells and in cells
transfected with GFP-Rab22a after treating them with ammonium
chloride (NH4Cl), which impairs lysosomal degradation [43]. We
reasoned that if the reduction of PrP
Sc by Rab22a was due to
increased lysosomal degradation, a block of the lysosomal function
with NH4Cl should revert its effect and result in unchanged or
increased PrP
Sc levels. On the the other hand, if the decrease of
PrP
Sc levels by Rab22a-expression was not due to increased PrP
Sc
degradation but rather to inhibition of PrP
Sc synthesis, NH4Cl
treatment should not interfere and we should stillobserve a decrease
in PrP
Sc levels. As expected from a block of lysosomal degradation
we observed anincrease intotalcellularPrPlevelsinNH4Cl-treated
cells (in both control cells transfected with GFP and in cells
transfected with GFP-Rab22a) when compared to untreated cells
(Figure 6B right panels). Similarly, PrP
Sc levels were also increased
in control cells (expressing GFP alone) treated with NH4Cl
(Figure 6B right panels). However, in contrast to total PrP, PrP
Sc
levels were reduced in GFP-Rab22a expressing cells, independently
of the presence of NH4Cl (Figure 6B right panels). These results
thereforesuggest that the observed reductionof PrP
Sc levels in GFP-
Rab22a expressing cells is due to impaired PrP
Sc production rather
than to increased degradation.
The Endosomal recycling compartment is the likely site
of prion conversion
Overall, the results described in the previous paragraph indicate
that the recycling of PrP through the ERC is required for scrapie
production. However, they do not allow us to discriminate
whether PrP
C to PrP
Sc conversion occurs within this compartment
Figure 5. Overexpression of GFP-Rab22a affects cellular distribution of PrP
C and reduces PrP
Sc levels. (A) ScGT1 cells were transfected
with GFP-Rab22a and immunolabeled for EEA-1 or PrP
C. Yellow color and arrowheads indicate colocalization. The quantification results (mean6s.e.m,
n=36) are presented as % of total signal in red (PrP) colocalizing with GFP-Rab22a (green). Increase in PrP
C (p=0,0011, t-test) in EE of GFP-Rab22a
expressing cells was detected. (B) GFP and GFP-Rab22a in transfected ScGT1 cells were analyzed on western blot using anti-GFP Abs. Band
corresponding to GFP and GFP-Rab22a are marked with arrows. Levels of PrP
Sc (PK+) and total PrP (PK2) were analyzed on western blot. The PrP
Sc
level (mean6s.e.m, n=3) in GFP-Rab22a expressing cells is presented as % of the PrP
Sc level in GFP expressing cells, which is considered as 100%.
Overexpression of GFP-Rab22a in ScGT1 cells causes reduction in PrP
Sc levels (p=0,015, t-test). (C) ScGT1 cells were transfected with GFP-Rab22a
(green) for 6 days and immunolabeled for PrP
Sc upon Gnd treatment using Saf32 mAb. Note that in contrast to control cells, PrP
Sc (red) cannot be
observed in GFP-Rab22a expressing cells. Scale bars represent 10 mm.
doi:10.1371/journal.ppat.1000426.g005
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involvement of the ERC in prion conversion, we overexpressed in
ScGT1 cells wild type and dominant-negative forms of Rab11,
which have been shown to modulate recycling through ERC.
Similar to what has been shown in other cell lines [44,45], we
found both Rab11wt-GFP and Rab11S25N-GFP in the Golgi, in
the ERC, and occasionally in peripheral vesicular structures that
were negative for EEA-1 (Figure S9 and data not shown). In
contrast to previous reports in CHO and BHK cells [44],
overexpression of Rab11S25N-GFP in ScGT1 cells did not
interfere with the transport of Tfn from EEs to the ERC (Figure
S9) but impaired its recycling from the ERC to the PM (Figure 7A).
Indeed, in contrast to control cells in which the majority of Tfn
was chased out of the cells after 45 min, in cells overexpressing
Rab11S25N-GFP exit of Tfn from the ERC was delayed. While a
significant amount of the protein was still detected inside the cells
after a 45 min chase period (Figure 7A upper panels), complete
clearance of Tfn occurred only after 90 min (data not shown).
Interestingly, compared to control cells, a higher amount of PrP
Sc
was observed to colocalize with Tfn in the ERC of transfected cells
(Figure 7A lower panels) indicating that PrP was also retained in
this compartment. Significantly, in these cells the levels of PrP
Sc
were slightly increased (Figure 7B). We also attempted to analyze
PrP
Sc levels in ScCAD and ScN2a cells expressing Rab11S25N-
GFP. However, due to increased mortality of Rab11S25N-GFP-
expressing cells we were not able to perform a quantitative analysis
of PK-resistant PrP levels. Nonetheless, immunofluorescence
analysis in the transfected cells revealed the presence of PrP
Sc in
these cells (data not shown), thus supporting the result obtained in
ScGT1 cells. Overall these data strongly suggest that PrP
Sc
conversion occurs in the ERC and imply that recycling from ERC
to the PM is not relevant to this process.
Figure 6. Overexpression of GFP-Rab22a does not induce PrP
Sc degradation. (A) GFP-Rab22a was expressed in ScGT1 cells for 3 days and
PrP
Sc and Alexa 546-dextran distribution was analyzed by immunofluorescence. Yellow color and arrowheads indicate colocalization between PrP
Sc
and GFP-Rab22a, while purple color indicates colocalization between dextran and LBPA (arrowheads) or PrP
Sc and LBPA (arrows). Scale bars represent
10 mm. (B) Control ScGT1 (ctrl) and ScGT1 transfected with GFP or GFP-Rab22 were either treated (+) or not (2) [13] with NH4Cl. Levels of GFP, GFP-
Rab22a, PrP
Sc (PK+) and total PrP (PK2) were analyzed on western blot. Tubulin levels represent control for equal loading. PrP
Sc levels were quantified
and plotted as a ratio between PrP
Sc and total PrP. Note that NH4Cl does not affect Rab22a-induced decrease in PrP
Sc levels (p=0,083, t-test).
doi:10.1371/journal.ppat.1000426.g006
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Conversion of PrP
C to PrP
Sc is the key event in prion
pathogenesis. Prion conversion is thought to occur at a site where
the two protein forms meet and are allowed to physically interact.
To date there is no direct evidence for the involvement of any
specific intracellular compartment in this event as several
compartments have been proposed to have a role in different cell
systems [11,12,13,16,17,32]. Based on analyses of the subcellular
localization of different PrP forms, lysosomes have been proposed
as a possible location for the conversion process [13,17,32].
However, contrasting data about PrP
C and PrP
Sc localization exist
[6,7] (and see introduction), underlying the need for a more
systematic and quantitative approach aimed at uncovering the site
of conversion. The inconsistencies in the reported localization of
different PrP forms are most likely related to the lack of PrP
Sc
antibodies that can distinguish between the two prion forms and
the need for protein denaturation by guanidine hydrochloride
(Gnd) to reveal PrP
Sc epitopes making such analyses quite difficult.
Because characterization of the intracellular localization of
different PrP forms can provide important clues about the
compartment where PrP
C to PrP
Sc conversion occurs, we
reassessed the subcellular distribution of PrP
C and PrP
Sc in three
different neuronal cell lines infected with different prion strains
(ScGT1 infected with RML, ScCAD infected with 139A and
ScN2a infected with 22L), which have been widely used as cellular
models for prion infection [26,27]. To clearly distinguish between
PrP
C and PrP
Sc we employed advanced imaging technology
complemented by quantitative image analysis, allowing us to
define the relative amounts of PrP
C and PrP
Sc in each subcellular
compartment after treating the cells with Gnd in immunofluores-
cence experiments (Figure S1, Methods and [28]). A similar
approach, based on thresholding of the lower PrP
C-derived
fluorescence in order to extract only the higher fluorescence
signal from PrP
Sc was recently reported by Veith and collegues in
N2a cells [46]. In agreement with the results from this group and
in contrast to previous reports in ScN2a and ScGT1-7 cells in
which standard immunofluorescence approaches were utilized
[13,17,32], we found only a small amount of PrP
Sc in LEs, arguing
against the involvement of this compartment in PrP
Sc production.
Instead, by quantitative fluorescence analysis we observed a
preferential localization of PrP
Sc in the endosomal recycling
compartment of all three cells lines tested (Figure 1 and Figure S2).
In support of these findings, a similar localization was recently
observed using cryo-immunogold electron microscopy on hippo-
campal sections from mice infected with the RML prion strain
[12]. These observations prompted us to further assess the
involvement of the endocytic pathways and specifically that of
Figure 7. Overexpression of Rab11S25N-GFP impairs recycling of transferrin and PrP
Sc from the ERC and increases PrP
Sc
production. (A) Distribution of Alexa 546-transferrin (Tfn) and PrP
Sc was analyzed in ScGT1 cells transfected with Rab11S25N-GFP for 3 days. Yellow
color shows colocalization between Rab11S25N-GFP and Tfn, magenta between Tfn and PrP
Sc, cyan between Rab11S25N-GFP and PrP
Sc and white
between all three proteins. Scale bars represent 10 mm. The quantification results (mean6s.e.m, n=45) are presented as % of total signal in blue
(PrP
Sc) colocalizing with Tfn (red) in untransfected or Rab11S25N-GFP expressing (green) cells (p=0,0014, t-test). (B) Levels of Rab11S25N-GFP, total
PrP and PrP
Sc were analyzed on western blot in control (ctrl) and transfected cells (Rab11S25N-GFP). The band corresponding to Rab11S25N-GFP is
marked by an arrow. The quantification results (mean6s.e.m. n=4) are plotted as percentage (%) of PrP
Sc levels in Rab11S25N-GFP transfected cells
in comparison to untransfected (ctrl) cells where PrP
Sc levels are considered to be 100% (p=0,03, t-test).
doi:10.1371/journal.ppat.1000426.g007
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Sc conversion. To
this aim we selectively inhibited PrP trafficking through the
different endocytic compartments using both pharmacological and
reverse genetic approaches in infected cells (see Figure 8) and
analyzed PrP
Sc levels under the different experimental conditions.
We demonstrated that EEs are not involved in PrP
Sc production.
Indeed, when we blocked PrP exit from EEs the levels of PrP
Sc
were drastically reduced and an accumulation of PrP
C in EEs was
observed (Figures 2A, 2C, 5A, 5B, S8B, S8C and S8D). Besides
ruling out the involvement of EEs in the conversion process, these
data indicate that PrP
C must exit EEs in order to be converted.
Furthermore, in line with previous observations [4] recycling from
EEs to the cell surface does not seem to play an important role in
PrP
Sc production (Figure S6). Therefore we analyzed the sorting
from EE to LE and/or to the recycling compartment. By
specifically reducing the number of LE by Alix depletion
(Figure 4 and Figure S5) we demonstrated that LE are not
involved in PrP
Sc production. In contrast, PrP sorting from EEs to
the ERC seems to be the crucial event in the conversion process.
In particular, we found that PrP
Sc levels are drastically reduced
when trafficking from EEs to the ERC is specifically impaired
(Figure 5 and Figure S8). We clearly demonstrate that this is not a
cell-type-specific effect. Indeed, we observed a decrease in PrP
Sc
when we overexpressed Rab22a in both ScGT1 (Figure 5) and
ScCAD (Figure S8) cells, where Rab22a has a clear effect in
inhibiting transport from EEs to ERC. In contrast, no reduction in
PrP
Sc was observed when Rab22a was overexpressed in ScN2a
cells, where Rab22a does not control this pathway (data not
shown).
In addition to PrP
Sc, other glycosylphosphatidylinositol (GPI)-
anchored proteins (GPI-APs) have also been shown to be retained
in the ERC and this retention is GPI-, sphingolipid- and
cholesterol-dependent [47,48]. Furthermore, retention of GPI-
APs in the ERC can be physiologically relevant, as in the case of
the Folate Receptor for which loss of retention in this
compartment (by removing its GPI anchor or by depleting
cholesterol) severely impairs folate uptake [49]. In the case of the
prion protein, either removal of the GPI anchor, its replacement
with a transmembrane domain or cellular cholesterol depletion
impairs scrapie formation in cell lines [50,51,52,53] even though
the anchor seems to be dispensable for the conversion process itself
[54,55,56]. In support of this hypothesis are the conclusions of a
recent study by McNally and colleagues suggesting that the GPI
anchor of PrP is important for the persistent infection of cells in
vitro [57]. These authors found that neural stem cells derived from
PrP null mice expressing only anchorless PrP cannot be
persistently infected, although production of PK resistant PrP
was detected in the first 96 hours after infection [57]. In
Figure 8. Schematic presentation of the effects of different treatments on endocytic pathways. Cargo internalized by clathrin-dependent
or raft-dependent pathways is first delivered to early endosomes (EE), where sorting towards either recycling pathway (ERC) or degradative pathway
(LE/lysosomes) occurs. Cargo destined to recycle can return to the plasma membrane (PM) either directly from the EE by a Rab4-controlled pathway,
or it can undergo Rab22-dependent sorting to the endosomal recycling compartment (ERC). From ERC cargo is returned to PM by Rab11-dependent
pathway. Cargo destined for degradation is first delivered to late endosomes (LE) and then to lysosomes, where final degradation occurs. LE act as a
second sorting platform in the cell, since from there cargo can still be diverted towards recycling pathway. In order to specifically inhibit direct PM
recycling from EE we expressed dominant negative Rab4 mutant coupled to GFP (GFP-Rab4N121I). Sorting to the ERC was impaired by
overexpression of wild-type Rab22a (GFP-Rab22a), while export from the ERC to PM was impaired by expression of dominant-negative Rab11
coupled to GFP (Rab11S25N-GFP). To impair late endosomal pathway we affected biogenesis of LE by downregulating Alix using RNAi technology,
which resulted in lower number of LE.
doi:10.1371/journal.ppat.1000426.g008
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to the Fc portion of human IgG1 heavy chain and lacking the GPI
anchor, is expressed in Prnp
0/0 mice it is not convertible and
delays the onset of the disease when expressed together with wild
type PrP [58]. Moreover, intracerebral inoculation of prions into
Prnp
0/0 mice expressing an anchorless form of PrP results in a
reduced titre of infectivity, different anatomical localization of
amyloid plaques and no obvious clinical signs of disease compared
to wild type mice [59]. This suggests that the GPI anchor,
although not essential for the conversion process, plays an
important role in its efficiency in vivo. Thus, it is possible that
the GPI anchor is necessary for mediating the targeting of PrP to
the correct intracellular site (and/or to a propitious membrane
domain) in order to sustain the conversion process. In this scenario
PrP retention in the ERC might be necessary in order to
concentrate prion proteins in a cholesterol enriched membrane
domain for a sufficient amount of time to promote conversion.
Indeed, by inhibiting PrP exit from the ERC using the Rab11
dominant-negative mutant, we found an increase in PrP
Sc levels,
supporting the hypothesis that prion accumulation in the ERC
stimulates PrP
Sc production. Furthermore, the observation that
cholesterol redistribution from other cellular compartments to
LEs, induced by U18666A treatment, impairs PrP trafficking from
EEs to the ERC (Figure 2C) suggests that cholesterol is not only
important for GPI-AP retention within the ERC, but might also be
required for its sorting from EEs to the ERC. Given that protein
sorting from EEs to the ERC is Rab22a-dependent [41,42] it is
possible that, similarly to Rab4 [60], cholesterol levels also
influence Rab22a function. However, this attractive possibility
remains to be explored.
The mechanism of PrP
C to PrP
Sc conversion remains unknown.
It has been proposed that the conversion process requires
interaction between PrP
C and PrP
Sc and is assisted by other
protein(s) [1]. However, despite years of effort this protein has not
been identified, partially due to the secondary responses of cells to
prion infection that render analysis more difficult [61,62]. Our
results suggest that if such a protein exists it encounters PrP in the
ERC, therefore narrowing down potential candidates. Alterna-
tively, the PrP
C to PrP
Sc conversion may not be mediated by a
specific protein but instead may depend on the local lipid
environment.
The observation that cholesterol depletion reduces PrP
Sc levels
has highlighted the importance of the lipid environment for
scrapie production [50]. Cholesterol and glycosphingolipids are
enriched in membrane microdomains, known as detergent-
resistant domains (DRMs) or lipid rafts [63]. They have been
implicated in various processes such as signal transduction,
endocytosis and cholesterol trafficking [64]. It has been proposed
that PrP
C to PrP
Sc conversion occurs within lipid rafts, since both
proteins were found to reside in such domains [65]. Recent
evidence suggests that lipid rafts are heterogeneous both in terms
of their protein and lipid content, and can be localized to different
regions of the cell [64]. Furthermore, it has been shown that the
endocytic route of GPI-APs is cell-type dependent and correlates
with their residence time in DRMs. In CHO and BHK cells,
transport of GPI-APs to the ERC or to late endosomes,
respectively, is accompanied by differential association to DRMs
[66]. Interestingly, PrP and Thy-1, another GPI-AP, were found
to reside in distinct lipid domains in rat and mouse brain [67].
Moreover, it has been shown that Thy-1 associates with rafts only
transiently [68] and that raft partitioning, or raft residence time,
can be modulated by subtle changes in lipid composition [69].
Therefore, a cholesterol-dependent retention mechanism in the
ERC could facilitate the efficient conversion of native prion
protein into the scrapie form, by segregating it into distinct
membrane domains or aggregates. Interestingly, ERC membranes
have been shown to be enriched in cholesterol in different cells
[24,70,71]. Furthermore, PrP association with specific lipid
domains in different cellular contexts may influence its cellular
transport and thereby determine the differential cellular suscep-
tibility to prion infection. In conclusion, our data, based on
observations in three different cell models of prion infection,
indicate that the ERC is a likely candidate for the intracellular site
of prion conversion. Furthermore, the fact that these results were
consistent for two different prion strains (RML and 22L) suggests
that this is a general mechanism. Although we cannot completely
exclude contributions by other compartments to prion conversion,
recent evidence, showing a localization of PrP
Sc in the recycling
endosomes of primary hippocampal neurons derived from infected
brains [12] supports our hypothesis, strengthening the case for the
role of the ERC in prion conversion in infected mouse models.
These results open the door to more targeted approaches to study
the factors involved in this central event of the disease and to
develop better therapeutic strategies.
Methods
Cell culture, reagents, antibodies, plasmids and oligos
GT1-1 cells (gift of Dr. Mellon P., University of California, San
Diego, USA) were infected with RML prion strain (gift of Dr.
Korth K., Heinrich Heine University Du ¨sseldorf, Germany) and
ScN2a cells infected with 22L prion strain (gift of Dr. Korth K.,
Heinrich Heine University Du ¨sseldorf, Germany) were cultured in
DMEM with addition of 10% FCS (Invitrogen). ScCAD cells
infected with 139A prion strain (gift of Dr. Laude H., Institut
National de la Recherche Agronomique, Jouy-en-Josas, France)
were cultured in DMEM:F12 (Invitrogen) with addition of 10%
FBS. U18666A was purchased from Calbiochem. All other
chemicals were purchased from Sigma. SAF32 and SAF61
monoclonal antibodies were purchased from SPI-BIO, while
POM1 monoclonal antibodies were purchased from Dr. A. Aguzzi
(Institute of Neuropathology, University Hospital Zurich, Zurich,
Switzerland). Anti-tubulin monoclonal antibodies were from
Sigma. Anti-flotillin-1 monoclonal antibodies were from BD
Transduction Laboratories. Anti-GFP antibodies and all the
fluorescently labeled secondary antibodies were purchased from
Invitrogen (Molecular Probes), as well as Lysosensor, fluorescently
tagged transferrin and dextran. Anti-EEA-1 antibodies were kind
gift of Dr. M. Zerial (Max Planck Institute of Molecular Cell
Biology and Genetics, Dresden, Germany) and anti-LBPA
antibodies were gift from Dr. J. Gruenberg (University of Geneva,
Geneva, Switzerland). Anti-Alix antibodies were gift from Dr. R.
Sadoul (Neurode ´ge ´ne ´rescence et Plasticite ´, E0108, INSERM/
Universite ´ Joseph Fourier, Grenoble, France). Anti-Rab22a
antibodies and GFP-Rab22a construct were kind gift of Dr. L.
Mayorga (Laboratorio de Biologı ´a Celular y Molecular, Instituto
de Histologı ´a y Embriologı ´a (IHEM-CONICET), Facultad de
Ciencias Me ´dicas, Universidad Nacional de Cuyo, Mendoza,
Argentina). Rab11wt-GFP and Rab11S25N-GFP were gift of Dr.
S.Mayor (National Centre for Biological Science (TIFR), Bellary
Road, Bangalore 560 065, India). Alix siRNA oligos were
published previously [39] and purchased from Dharmacon. All
the other siRNA used in the study were predesigned ON
TARGETplus SMARTpool from Dharmacon.
Treatment of ScGT1 cells with U18666A
U18666A was reconstituted according to producer’s instructions
and used in DMEM+10% FCS at 5 mM concentration for
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cells. During the 6 day-treatment, medium containing U18666A
was changed every 2 days. To analyze PrP levels on western blot
cells were lysed and lysates were either treated or not with
Proteinase K as described. PrP was revealed by SAF61 antibodies.
For immunofluorescence analysis cells were washed after the 6 day
treatment, and processed as described below in Immunofluores-
cence analysis.
Transient transfections
ScGT1-1 cells were transfected at 50% confluence using
FuGENE6 (Roche Diagnostic) for DNA constructs according to
manufacturers protocol. Transfection of siRNA in ScGT1-1 was
done using HiPerFect (Qiagen). To downregulate Alix and
Rab22a, 250 nM oligo and 500 nM oligo respectively was used
with 10 ml of HiPerFect per 60 mm dish, while 3 ml of HiPerFect
was used per well for cells grown in 24-well plate. Hyperfect was
mixed with siRNA in DMEM without FBS, incubated for 10 min
at room temperature and added to the cells. Transfection of
ScCAD and ScN2a cells with both DNA constructs and siRNA
was done using Lipofectamine 2000 (Invitrogen), according to
producer’s protocol. In order to detect the effect on PrP
Sc levels,
both silencing and overexpression of proteins were required during
6-day period. Therefore in all the experiments siRNA and
plasmids, except of pEGFP were transfected twice (3 days post-
transfection a second transfection was performed) during 6 days.
Endocytosis of fluorescently labelled transferrin and
dextran
ScGT1-1, ScCAD and ScN2a cells (200000) were grown on
coverslips for 2 days. For steady state localization, 50 mg/ml of
Alexa-labeled transferrin was added to the medium for 15 minutes
at 37uC. In pulse and chase experiment 50 mg/ml of transferrin
was added to the medium for 15 min at 37uC. The cells were
extensively washed with PBS and Alexa-labeled transferrin was
chased out of the cells with the excess (5 mg/ml) of unlabeled
transferrin for indicated time period.
To follow dextran endocytosis by immunofluorescence, cells
were first incubated in 10% FBS at 4uC for 30 min followed by
30 min incubation with 3 mg/ml of Alexa-dextran at 37uC. Cells
were then extensively washed with PBS and chased in the medium
deprived from dextran for additional 3 h at 37uC.
Immunofluorescence analysis
For immunofluorescence analysis, cells were fixed with 2%
paraformaldehyde for 30 min unless differently indicated and
permeabilized with 0,1% of Triton X-100/PBS. To analyze PrP
Sc
cells were additionally incubated in 6 M guanidine-hydrochloride
for 10 min after permeabilization. Cells were then blocked in 2%
BSA for 30 min unless differently indicated, following by 30 min-
incubation with primary and secondary antibodies respectively. For
immunofluorescence analysis of Alexa-labeled dextran cells were
fixed in 4% PFA for 4 h and further processed as described. When
filipin staining was used, cells were fixed with 4% PFA for 60 min
andblocked with 0,2%BSA/PBS. Filipin (250 mg/ml)wasadded to
blocking solution and additional 30 min-incubation was performed
after incubation with secondary antibodies. Immunofluorescence
was analyzed by high-resolution wide-field microscope Marianas
(Intelligent Imaging Innovations) using a 636oil objective.
Image acquisition, processing and quantification
When PrP
Sc was analyzed, the auto-scaling (min/max) of signal
detection was used to record only maximal signal intensities.
Briefly, the exposure time (100 ms) used to detect PrP
Sc
fluorescence was insufficient to detect significant signal coming
from PrP
C. The camera settings were then adjusted to record only
the range of PrP
Sc-derived fluorescence signal. The images were
deconvolved using constrained iterative algorithm in Slidebook
software (Intelligent Imaging Innovations). Colocalization was
quantified by intensity correlation coefficient-based (ICCB)
analysis using Imaris software (Bitplane) or JACoP (http://rsb.
info.nih.gov/ij/plugins/track/jacop.htlm). Statistical analysis of
the correlation of the intensity values of either green and red pixels
or blue and red pixels in dual-channel image was performed using
Pearson’s and Menders’s coeficient and Van Steensel’s approach
[72]. The amount of total fluorescent signal in one channel
overlapping with the total fluorescent signal in the other channel
was presented. To quantify the number of LBPA and Lysosoensor
positive vesicles in control cells or cells transfected with Alix
siRNA, the vesicles were counted by particle analysis using Image
J software (http://rsb.info.nih.gov/ij).
Detergent Resistant Microdomain (DRM) analysis by
sucrose density gradients
Control ScGT1 and U18666A-treated cells grown to confluence
in 150 mm dishes were harvested in cold PBS and resuspended in
1 ml lyses buffer (1% TX-100, 10 mM Tris-HCl pH 7.5, 150 mM
NaCl, 5 mM EDTA), left on ice for 20 minutes and passed 10
times through 22-gauge needles. Lysates were mixed with an equal
volume of 85% sucrose (w/v) in 10 mM Tris-HCl pH 7.5,
150 mM NaCl, 5 mM EDTA, placed at the bottom of a
discontinuous sucrose gradient (30–5%) in the same buffer and
ultracentrifuged at 200,000 g for 17 hours at 4uCi na n
ultracentrifuge (SW41 rotor from Beckman Instruments, Full-
erton, CA, USA). Twelve fractions were harvested from the top of
the gradient. A white light-scattering band identified in fraction 5
at the interface between 5 and 30% sucrose, contained DRM
domains. Samples were TCA precipitated and proteins were
analyzed by western blotting.
Protein analysis
Cells were grown to confluence in 60 mm dishes and lysed in
500 ml of Lyses buffer (0,5% triton X-100, 0,5% DOC, 100 mM
NaCl, 10 mM Tris-HCl pH 8). To analyze PrP
Sc by western blot,
lysates (500 mg of protein) were treated with 20 mg/ml of
Proteinase K (PK) for 30 min on 37uC and protein content was
pelleted by centrifugation at 14000 rpm and 4uC for 1 hr. Pellets
were resuspended in Laemmli buffer and proteins were analyzed
by western blotting. In contrast to PrP
C, which is completely
degraded by PK, only partial degradation of PrP
Sc occurs in this
condition [73]. Other proteins, including total PrP were analyzed
by western blotting from 25 mg of total lysate.
Statistical analysis
T-test was used for statistical analysis of the data. The
differences were considered significant when p,0.05.
Supporting Information
Figure S1 Acquisition adjustments to detect only PrP
Sc by
immunofluorescence. (A) Control ScGT1 cells and cells treated
with 1 mg/ml of dextran sulphate for 6 days were lysed, incubated
or not with 20 mg/ml of Proteinase K (PK) and levels of total PrP
or PK resistant PrP (PrP
Sc) were analyzed on western blot using
SAF61 mAb. Note that no PrP
Sc could be observed upon
treatment with dextran sulphate. (B) Control ScGT1 cells and
(C) cells treated with 1 mg/ml of dextran sulphate for 6 days were
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described in Methods. PrP
Sc was revealed by SAF32 mAb and
analyzed by high resolution wide-field microscope Marianas
(Intelligent Imaging Innovations). Exposure times used to acquire
images were 100 ms for PrP
Sc and 500 ms for PrP
C. Auto scaling
option (min/max) was used to permit detection of only maximal
signal intensities. Note that those settings permitted to detect only
PrP
Sc signal with 100 ms as seen in control cells, which was
completely absent in cells cured by dextran sulphate treatment
(compare b and c upper panels).
Found at: doi:10.1371/journal.ppat.1000426.s001 (0.96 MB TIF)
Figure S2 Steady-state distribution of PrP
Sc in ScCAD and
ScN2a cells infected with different prion strains. PrP
Sc was
revealed using SAF32 mAb, after denaturation with Gnd as
described in Methods and colocalization with Giantin (Golgi),
Lamp-1 (lysosomes), EEA-1 (early endosomes) and Alexa 488-
transferrin (Tfn); marker for the perinuclear recycling compart-
ment) was analyzed. Yellow colour indicates colocalization. Note
that PrP
Sc significantly colocalizes with Tfn in the ERC of both
cell lines. Scale bars 10 mm.
Found at: doi:10.1371/journal.ppat.1000426.s002 (1.57 MB TIF)
FigureS3 U18666A treatmentreduces PrP
SclevelsinScN2a cells
and impairs trafficking of Tfn and PrP, without affecting PrP
C
distribution in detergent resistant domains (DRMs). (A) Control
ScN2a cells and cells treated with 1 mM U18666A for 6 days were
lysed and levels of total PrP or PrP
Sc were analyzed on western blot
using SAF61 mAb. To reveal PrP
Sc lysates were incubated with
20 mg/ml of Proteinase K (PK). Note that no PrP
Sc could be
observed in U18666A treated cells. (B) Lysates from control and
U18666A treated ScN2a cells were applied on sucrose gradient and
ultracentrifuged at 200000 g for 16 hr. Twelve fractions were
collected and proteins were precipitated using 10% of trichlor-
oacetic acid. PrP and flotillin-1 contents in each fraction were
analyzed on western blot using SAF61 mAb and flotillin-1 mAb.
Fractions 4–7 correspond to detergent resistant membranes (DRM)
based on distribution of flotillin-1, which is mainly present in
DRMs. In ScN2a cells PrP is distributed in DRMs and U18666A
treatment does not change its distribution. (C) Steady-state
localization of PrP
C was analyzed in control (ctrl) and U18666A-
treated cells after 6 days of treatment. The effect of the treatment
was assessed by cholesterol accumulation in LE based on filipin
staining shown in blue. Yellow colour represents colocalization
between PrP
C and EEA-1. Note that in control condition PrP
C and
cholesterol were exclusively localized at the cell surface, while upon
U18666A treatment, cholesterol was redistributed to LE and PrP
C
was enriched in EEA-1 positive EE. (D) Alexa 488-Tfn was
internalized for 15 min and its subcellular distribution was analyzed
in control and U18666A-treated cells. Yellow colour represents
colocalization between EEA-1 and Alexa 488-Tfn. Note that in
U18666A-treated cells Alexa 488-Tfn is confined to EE and does
not accumulate in the ERC. Scale bars 10 mm.
Found at: doi:10.1371/journal.ppat.1000426.s003 (2.26 MB TIF)
Figure S4 U18666A blocks EE to LE traffic in ScGT1 cells. (A)
To study traffic from early (EE) to late endosomes (LE), control
ScGT1 cells were either incubated with Alexa 488-dextran for
15 min and then fixed, permeabilized and immunolabeled for
EEA-1, or additionally incubated in a dextran-free medium for 3 h
and then fixed, permeabilized and immunolabeled for LBPA.
Yellow colour and arrowheads indicate colocalization. In control
cells a diffuse cholesterol distribution was revealed by fillipin
staining. Inset represents magnification of the boxed area. Upon
15 min pulse dextran was internalized into EE and then was
chased to LE upon subsequent incubation in dextran-free
medium. (B) The experiment described in (A) was performed in
ScGT1 cells treated with 5 mM U18666A. Characteristic choles-
terol laden late endosomes were revealed with both filipin staining
(blue) and immunolabeling for LBPA (red, lower panels). Magenta
colour represents colocalization between filipin and LBPA in lower
panels. Yellow colour and arrowheads indicate colocalization
between dextran and EEA-1. Treated cells were able to internalize
dextran into EE upon 15 min pulse, but in contrast to control cells
they were not able to deliver dextran to the LE after 3 hr chase
period. Scale bars 10 mm.
Found at: doi:10.1371/journal.ppat.1000426.s004 (2.47 MB TIF)
FigureS5 Alix downregulation inScGT1 and ScCAD cells causes
reduction in the number of late endosomes/lysosomes without
affectingPrP
Sclevels.ScGT1 andScCADcellswere transfectedwith
either control oligo (ctrl ol) or RNAi against Alix (siAlix) during six
days. (A) ScGT1 cells were let to internalize Lysosensor, which emits
fluorescence only in acidic compartments followed by fixation,
permeabilization and immunolabeling for LBPA. Scale bars 10 mm.
The number of Lysosensor and LBPA positive vesicles was analyzed
by Image J software. Results are presented as number of vesicles
(mean6s.e.m) counted in 60 cells from 2 different experiments.
Significant decrease in number of Lysosensor and LBPA positive
vesicles was observed in Alix depleted ScGT1 cells when compared
to control cells (p=0,0011, t-test). (B) Alix and PrP
Sc levels were
analysed by western blot in lysates from ScCAD cells transfected
with Alix siRNA for 6 days. Levels of PrP
Sc were analyzed after the
treatmentwith20 mg/mlofPKusingSAF61mAb.PrP
Sclevelswere
not affected upon Alix downregulation. Similar results are obtained
for ScGT1 cells (Figure 4).
Found at: doi:10.1371/journal.ppat.1000426.s005 (1.26 MB TIF)
Figure S6 Expression of GFP-Rab4wt or GFP-Rab4N121I in
ScGT1 and ScN2a cells does not influence PrP
Sc levels. Control
ScGT1 and ScN2a cells and cells transfected with GFP-Rab4
constructs for 6 days were lysed and levels of GFP-Rab4 were
analyzed on western blot using anti-GFP Abs. Bands correspond-
ing to GFP-Rab4wt and GFP-Rab4N121I were marked by
arrows. Levels of PrP
Sc were analyzed after the treatment with
20 mg/ml of PK using SAF61 mAb.
Found at: doi:10.1371/journal.ppat.1000426.s006 (0.21 MB TIF)
Figure S7 Rab22a regulates transferrin sorting to ERC and
PrP
Sc production in ScGT1 cells. (A) Overexpression of GFP-
Rab22a in ScGT1 cells inhibits Tfn sorting to ERC. ScGT1 cells
were transfected with GFP-Rab22a and allowed to internalize
Alexa 546-transferrin (Tfn) for 5 and 15 min. Yellow colour and
arrowheads indicate colocalization. Scale bars 10 mm. The
quantification results (mean6s.e.m, n=36) are presented as %
of total signal in red (Tfn) colocalizing with GFP-Rab22a (green).
Increase of Tfn (p=0,0099, t-test) in EE of GFP-Rab22a
expressing cells was detected. Note that Tfn was not able to reach
ERC after 15 min internalization. (B) Rab22a depletion reduces
PrP
Sc level in ScGT1 cells. Rab22a and PrP
Sc levels were analyzed
by western blot in lysates from untransfected cells (ctrl), or cells
transfected with either control oligo (ctrl ol) or RNAi against
Rab22a (siRab22) for 6 days. To reveal PrP
Sc the lysates were
treated with 20 mg/ml of Proteinase K (PK) and SAF61 mAb was
used on western blot. Around 60% downregulation in Rab22a
level was observed in cells transfected with siRab22, 6 days post-
transfection. The band corresponding to Rab22a is marked by an
arrow. Asterisk indicates unspecific band as a control for equal
loading. PrP
Sc levels were quantified and the results (mean6s.e.m,
n=3 experiments) are presented as % of PrP
Sc level in control,
untransfected cells, which is considered as 100%. Around 50%
Prion Conversion Compartment
PLoS Pathogens | www.plospathogens.org 13 May 2009 | Volume 5 | Issue 5 | e1000426reduction in PrP
Sc levels was observed in Rab22a depleted cells
(p=0,032, t-test).
Found at: doi:10.1371/journal.ppat.1000426.s007 (1.97 MB TIF)
Figure S8 Overexpression of GFP-Rab22a affects cellular
distribution of Tfn and PrP
C and reduces PrP
Sc levels in ScCAD
cells. (A) ScCAD cells transfected with GFP-Rab22a for 6 days
were fixed and immunolabeled for EEA-1 (upper panels). In the
parallel experiment (lower panels) transfected cells were let to
internalize Alexa 546-Tfn for 15 min. Yellow colour represents
colocalization between GFP-Rab22a and EEA-1 or GFP-Rab22a
and Tfn. GFP-Rab22a was colocalizing with EEA-1 in EE, but it
was also present in tubular structures (arrowheads) and EEA-1
negative vesicles (arrows). In contrast to control cells in GFP-
Rab22a-expressing cells Tfn was not accumulating in the ERC,
but was distributed instead in GFP-Rab22a positive compartment.
(B) Cells transfected with GFP-Rab22a were fixed and immuno-
labeled for PrP
C using Saf32 mAb and EEA-1 using anti-EEA-1
Ab. White colour and arrowheads represents colocalization
between PrP
C, GFP-Rab22a and EEA-1. (C) GFP and GFP-
Rab22a in transfected ScGT1 cells were analyzed on western blot
using anti-GFP Abs. Levels of PrP
Sc (PK+) and total PrP (PK2)
were analyzed on western blot. (D) PrP
Sc was additionally
analyzed by immunofluorescence in GFP-Rab22a transfected cells
upon Gnd denaturation and immunostaining with POM-1 mAb.
While PrP
Sc was revealed in control cells, no signal for PrP
Sc was
observed by both western blot analysis and immunofluorescence in
GFP-Rab22a-expressing cells. Scale bars 10 mm.
Found at: doi:10.1371/journal.ppat.1000426.s008 (1.69 MB TIF)
Figure S9 Rab11wt-GFP and Rab11S25N-GFP are partially
localized in the ERC and in peripheral vesicles. ScGT1 cells were
transfected with Rab11 constructs for 6 days. Alexa 546-
transferrin was internalized for 15 min to label ERC. Yellow
colour represents colocalization. Scale bars 10 mm.
Found at: doi:10.1371/journal.ppat.1000426.s009 (1.69 MB TIF)
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